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Background:Early recurrent stenosis of the cephalic arch in autogenous arteriovenous access for hemodialysis is a common
problem that requires stenting to prevent thrombosis. Because the results of stenting are unsatisfactory, we compared the
efficacy of stent grafts with bare stents in these patients.
Methods: All patients who presented with recurrent cephalic arch stenosis >50% within 3 months of successful balloon
angioplasty were randomized to have angioplasty and stenting with either a bare nitinol stent or a stent graft. Outcome
was assessed by angiography 3months later. Restenosis was defined as>50% narrowing of the stent lumen or of the vessel
margin up to 0.5 cm adjacent to the stent. There were no exclusions.
Results: This report includes data on the outcome of 25 consecutive patients with recurrent cephalic arch stenosis who
were treated from April to August 2006. At 3 months, three patients had died and one had undergone a renal transplant.
The 21 patients who had angiography at 3 months had patent stents. Restenosis rates were seven of 10 (70%) in the bare
stent group and two of 11 (18%) in the stent graft group (P  .024). Life-table analysis at 3 and 6 months showed that
primary patency was 82% in the stent graft group and 39% in the bare stent group. One-year primary patency was 32% in
the stent graft group and 0% in the bare stent group (P .0023). During a mean follow-up of 13.7 months, nine patients
died, four in the bare stent group and five in the stent graft group. Two patients in the stent graft group had received a
renal transplant. The number of interventions per patient-year was 1.9 in the bare stent group and 0.9 in the stent graft
group (P  .02).
Conclusions: The use of stent grafts in angioplasty for recurrent cephalic arch stenosis significantly improved short-term
restenosis rates and long-term patency compared with the use of bare stents. The significant improvement that emerged
during the study caused accrual of patients to be halted for ethical reasons. This study altered our usage of stents for
venous stenoses in arteriovenous accesses by eliminating bare nitinol stents in favor of stent grafts. ( J Vasc Surg 2008;
48:1524-31.)The type of hemodialysis access and its preservation
greatly influence the quality of life and survival of pa-
tients undergoing hemodialysis. The National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines for vascular access recommend pri-
mary placement of autogenous hemodialysis accesses
in preference to expanded polytetrafluoroethylene
(ePTFE) grafts and central venous catheters because
From the Department of Surgery, Vascular Access Centera, Department of
Radiology, Interventional Unitb, and Infectious Diseases Unit,c Shaare
Zedek Medical Center (affiliated with the Faculty of Medicine of the
Hebrew University).
Clinical Trials Registration Identifier: NCT00318435.
Competition of interest: none.
This work was presented at the Cardiovascular and Interventional Radiology
Society of Europe (CIRSE) Annual Meeting, Athens, Greece, Sep 8-12,
2007.
Additional material for this article may be found online at www.jvascsurg.
org.
Correspondence: Dr Oded Olsha, Department of Surgery, Shaare Zedek
Medical Center, PO Box 3235, Jerusalem 91031, Israel (e-mail:
oolsha@gmail.com).
0741-5214/$34.00
Copyright © 2008 Published by Elsevier Inc. on behalf of The Society for
Vascular Surgery.doi:10.1016/j.jvs.2008.07.071
1524autogenous accesses have fewer complications and longer
durability,1 but autogenous arteriovenous accesses (AVA)
are also subject to dysfunction and failure.
Endovascular percutaneous transluminal angioplasty
(PTA) has become an accepted alternative treatment to
surgical revision for hemodialysis access–related venous
stenoses and occlusions.2 However, the patency rates in the
follow-up period are low because of the high incidence of
restenosis due to intimal hyperplasia.3 Bare stents have
been used to improve AVA patency for the last 20 years.4
No prospective studies have been done on endovascular
intervention for central vein stenosis or occlusion, but bare
stents have demonstrated better patency rates than PTA
alone in most studies.5 Even after stent placement, neoin-
timal hyperplasia is still the major reason for restenosis.6
The cephalic vein forms part of the outflow conduit for
radial–cephalic autogenous AVAs and is the sole outflow
conduit for brachial–cephalic autogenous AVAs. It has
recently been suggested that a focal area of the cephalic vein
is prone to the development of hemodynamically signifi-
cant stenosis, in what is now termed the cephalic arch.3,7
This is the perpendicular portion of the cephalic vein in the
region of the deltopectoral groove before its junction with
the axillary or subclavian vein. Stenosis in this region is
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We have performed angioplasty with bare stents if the result
of PTA was poor or if there was early restenosis (3
months). Restenosis in this region is common, and re-
peated angioplasty is necessary to maintain patency. How-
ever even after deployment of bare stents, patency after
stenting of AVAs is unsatisfactory due to the rapid devel-
opment of in-stent stenosis.8
Because of the problem of restenosis due to intimal
hyperplasia after stenting in the cephalic arch, we con-
ducted a prospective randomized trial comparing the use of
stent grafts as an alternative to bare stents in early recurrent
cephalic arch stenosis after PTA.
MATERIALS AND METHODS
The protocol of this prospective randomized trial was
reviewed and approved by the Shaare Zedek Medical Cen-
ter Ethics Committee, and all patients gave written in-
formed consent before entering the trial. Our dialysis access
center is a regional referral center. In 2006, 289 new AVAs
were created in our center, 245 (85%) of which were
autogenous. Starting April 2006, 50 hemodialysis patients
with recurrent cephalic arch stenosis were to be random-
ized to receive either a bare nitinol Luminex vascular stent
or a Fluency Plus stent graft (both from Bard Peripheral
Vascular, Angiomed GmbH & Co Medizintechnik KG,
Karlsruhe, Germany). These stents consist of a self-
expanding nitinol skeleton, the stent graft being encapsu-
lated with two ultrathin layers of ePTFE. This report is
limited to the 25 patients who were enrolled in the trial.
Patient population and selection. The study was
restricted to patients with recurrent cephalic arch stenosis
3 months of a previous successful PTA. Patients with
suspected restenosis were referred for angiography and
endovascular intervention when necessary. Restenosis was
suspected if there were suggestive findings:
● clinical signs of increased pressure—strong pulse, weak
thrill;
● dialysis monitoring and surveillance criteria—high static
pressure anddecreased efficiency, calculated asKt/V (the
fractional clearance of urea as a function of its distribution
volume) – dialyzer clearance of urea [K, in L/min] 
treatment time [t, in min] divided by the volume of
distribution of urea in the body [V, in mL]); and
● Doppler ultrasound findings (blood flow velocity
4.0m/s at the cephalic arch with an insonation angle
of 60° or a peak systolic velocity ratio between the
stenosis and an adjacent segment of 3.0).
These findings were observed either by the dialysis
team and confirmed by Doppler ultrasound outside of the
routine follow-up, or during routine periodic clinical exam-
ination combined with a Doppler ultrasound examination
performed by one of the vascular surgeons. If Doppler
ultrasound confirmed the finding of a 50% stenosis, pa-
tients were referred for endovascular intervention.
Doppler ultrasound examinations. The Acuson
SEQUOIA 512 (Mountain View, Calif), with a 6L3 multi-frequency linear array transducer, was used for all Doppler
ultrasound examinations. Patients were examined lying su-
pine with the head raised to 30° and with the arm abducted
to 30° to 45°. The standard examination included blood
flow measurement, direct examination of the anastomosis,
and examination of the entire length of the vein, with
display of the cephalic arch, the confluence with the sub-
clavian vein, and the proximal innominate vein. All preop-
erative and follow-up Doppler ultrasound examinations in
our access center are performed by one of the two dedicated
access surgeons, one of whom is also an active registered
vascular technician.
Endovascular interventions and randomization.
All interventions were performed as outpatient procedures.
Patients were monitored with pulse oximetry, noninvasive
automatic blood pressure measurement, and limb lead elec-
trocardiographic display. Intravenous fentanyl citrate and
midazolam were used to provide moderate sedation.
Antegrade puncture of the access was performed near
the arteriovenous anastomosis, preferably at the arterial
hemodialysis puncture site. A 19- or 21-gauge needle was
used to advance a guidewire into the vein. Multiple projec-
tions were not used because of difficulty in obtaining
adequate angulation of the x-ray tube and image intensifier
when imaging the shoulder. Changing patient position was
not considered acceptable because of the use of sedation.
However, multiple projections were not considered neces-
sary because the stenosis had already been diagnosed by
Doppler ultrasound, which is known to be accurate for this
purpose.9 Stenoses were assessed by measuring their nar-
rowest point as a percentage of the nearest normal diameter
cephalic vein. Calibrated calipers were used for the mea-
surement.
Patients were randomized to receive either a bare stent
or a stent graft after digital subtraction angiography iden-
tified a lesion for dilation (50% stenosis) and before
deployment of the stent. Randomization was by lottery
using envelopes containing one of the two interventions
(25 bare stent and 25 stent graft envelopes). A 5000 IU
bolus of heparin was injected, and balloon angioplasty was
performed using a high-pressure (25 to 30 atm) 4-cm-long
Conquest PTA Balloon Dilatation Catheter (Bard Periph-
eral Vascular, Inc, Tempe, Ariz). Cutting balloons were not
used in this study.
Balloon diameter was determined by visually approxi-
mating the diameter of the cephalic vein adjacent to the
focal area of narrowing and comparing the size of the
inflated balloon with the size of the adjacent nonstenosed
cephalic vein at the time of angioplasty. The balloon was
inflated to the point of resolution of the waist up to the
maximum pressure allowed by the manufacturer as neces-
sary. Two inflations were performed: the first for 60 sec-
onds and the second, after deflation, for a further 20
seconds.
Bare stent or stent graft deployment was performed
using the same approach. After stent placement, angio-
plasty was repeated with low-pressure balloon inflation to
further anchor the stents. The balloon catheters and
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stasis was obtained with manual compression or suture of
the puncture site.
Follow-up after stent deployment, and end points.
The results of the study were summarized to May 2008.
Clinical follow-up examinations and surveillance with du-
plex ultrasound scanning were performed 1month after the
intervention and every 3 months thereafter for all pa-
tients.10,11 All Doppler ultrasound examinations were con-
ducted in the same manner and in the same position as the
standard follow-up examination conducted for any patient
with an AVA in our center, by the same two vascular
surgeons using the same equipment, which is standard for
all patients in our center. The examiners were not blinded
to the type of stent used.
After angiography at 3 months, the patients entered our
regular surveillance program,where follow-upwas continued.
Patients were referred for an examination outside of this
schedule if the dialysis staff observed prolonged bleeding time
at the puncture site, an increase in venous counterpressure
during dialysis, or reduced dialysis efficiency.
The end point for the study was stenosis of the stent of
50% at 3 months (primary stent patency) as determined
by angiography. In-stent restenosis was defined as 50%
narrowing of the stent lumen. In-segment restenosis was
defined as 50% narrowing of the vessel margin up to 0.5
cm adjacent to the stent. Angiography was scheduled for 3
months after stent deployment in all patients, if it had not
been performed beforehand for suspected restenosis.
Patients were examined every 3 months thereafter by
Doppler ultrasound according to our usual follow-up cri-
teria.10,11 Further interventions were initiated as necessary
according to the clinical or Doppler ultrasound findings.
Follow-up was to be terminated with loss of the shunt,
renal transplantation, or the death of the patient.
Outcomes and statistical analysis. In addition to
hospital files, separate records were kept for each patient in
the study group comprising all Doppler ultrasound exami-
nations, operation notes, invasive radiology reports, and
follow-up data.
We selected the “universal study size” of 25 patients in
each arm to test the hypothesis that use of stent grafts will
result in significantly improved patency over bare stents,
with the option of extending the study if a nonsignificant
trend appeared after 50 patients were enrolled. We found
no published studies in the medical literature comparing
bare stents with stent grafts for stenoses in AVAs so no
statistical basis was available to enable calculation of the
required size and power of the study groups. For the same
reasons no interim statistical analysis was scheduled.
Postintervention primary stent patency was defined as
the interval between stent deployment and the time of the
first subsequent intervention. Postintervention functional
stent patency was defined as the interval between stent
deployment and stent occlusion or access abandonment
after all percutaneous reinterventions.12
Statistical analysis was done independently by one of the
authors (D.R.),whowas blinded to the twogroups. Statisticalsignificance was determined by the two-tailed Fisher exact
test. Analysis of patency was by the life-table analysis meth-
od,13-15 and the log-rank test was used for comparison of the
survival curves. Statistical significance was set at P .05.
RESULTS
From April to August 2006, 25 patients with early (3
months) cephalic arch restenosis after successful PTA had
angioplasty and stent deployment. All of the patients had an
autogenous brachial–cephalic AVA. All of the patients with
a finding of significant stenosis on Doppler ultrasound also
had a 50% stenosis on angiography. No patients were
excluded from the study. Patients in both groups had
similar clinical and demographic characteristics (Table I).
Mean (standard error of the mean) percentage stenosis for
the bare stent group and the stent graft group was 77%
(3.4%) and 77% (2.7%), respectively. Mean length of steno-
sis was 2.5 cm (median, 2.1; range, 0.9-4.5 cm) in the bare
stent group and 2.4 cm (median, 2.3; range, 0.9-4.8 cm) in
the stent graft group. The mean number of previous PTAs
was 2.8 (range 1-8) and 2.9 (range 1-6), respectively.
There was no statistically significant difference between the
two groups in any of these numeric variables.
After randomization, bare stents were deployed in 12
patients and stent grafts were deployed in 13 (Table II). All
deployments were initially successful, giving a technical suc-
cess rate of 100%. All patients were found to have a patent
AVA at the initial 1-month follow-up Doppler ultrasound
study. Ten patients with bare stents and 11 with stent grafts
also had angiography at 3 months. Three other patients (2
from the bare stent group and 1 from the stent graft group)
died before the scheduled 3-month angiography follow-up. A
fourth patient from the stent graft grouphad a renal transplant
before the scheduled angiography. The stents in these 4
patients were all patent at the 1-month Doppler ultrasound
Table I. Demographic and clinical characteristics for






Patients, No. 12 13
Females, No. (%) 3 (25) 6 (46)




Time to stent after AVA
creation, median
(mean, range), mon 21.2 (20; 6-36) 24.3 (28; 11-60)
Stenosis, mean  SEM, % 77%  3.4% 77%  2.7%
Stenosis length, mean
(range), cm 2.5 (0.9-4.5) 2.4 (0.9-4.8)
Previous angioplasties,
mean (range), No. 2.8 (1-8) 2.9 (1-6)
AVA, Arteriovenous access, SEM, standard error of the mean.
aLuminex stent, Bard Peripheral Vascular, Angiomed GmbH&Co, Mediz-
intechnik KG, Karlsruhe, Germany.
bFluency stent, Bard Peripheral Vascular.examination.
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sis rate) between the twogroupswas notedduring the study at
the initial 3-month angiography. At every angiography after
the first 20 deployments, the blinded results were presented to
one of the authors (D.R.), and differenceswere analyzed until
statistical significance (P .05) was reached when 25 patients
had been treated. Because of the significant difference in
outcomes for the two types of stent in the interim analysis, the
accrual of patients was halted, and all patients with early
restenosis at the cephalic arch were offered stent grafts.
Angiography at 3 months (Table III) showed that all
the AVAs examined were patent. Two patients in the bare
stent group died before the angiography at 3 months. One
patient in the stent graft group died and one patient re-
ceived a renal transplant before angiography. Restenosis of
50% was detected in seven of the 10 patients (70%) with
bare stents who had angiography, all of which were in-stent
restenosis, and in two of the 11 patients (18%) with stent
grafts (P  .024, 95% confidence interval [CI], 1.03-
14.38), both of which were in-segment restenosis in the
segment adjacent to the stent. The three patients who died
and the transplant recipient all had patent AVAs byDoppler
ultrasound imaging at their 1-month follow-up.
After the initial planned angiography at 3 months, all
patients continued in our routine surveillance program.




(n  12), No. (%)a
Stent graft
(n  13), No. (%)b
Technical success 12 (100) 13 (100)
DUS follow-up 12 (100) 13 (100)
Died during follow up 2 1
Renal transplant during
follow-up 0 1
Angiography follow-up 10 (83) 11 (85)
Primary patencyc 12 (100) 13 (100)
DUS, Doppler ultrasonography.
aLuminex stent, Bard Peripheral Vascular, Angiomed GmbH&Co, Mediz-
intechnik KG, Karlsruhe, Germany.
bFluency stent, Bard Peripheral Vascular.
cDocumented by DUS or angiography, or both.









Restenosis 50% 7 (70) 2 (18) .024
In-stent restenosis 50% 7 (70) 0 .001
In-segment restenosis 50% 0 2 (18) .262
Target lesion reintervention 7 (70) 2 (18) .024
NS, Not significant.
aLuminex stent, Bard Peripheral Vascular, Angiomed GmbH & Co Mediz-
intechnik KG, Karlsruhe, Germany.
bFluency stent, Bard Peripheral Vascular.The patients were monitored for an average of 13.7months(range, 1.7-21.6 months) after stenting. Nine patients died
during follow-up, and two had renal transplants. In the
bare stent group, four patients died, none received a trans-
plant, and one occluded. In the stent graft group, five
patients died, 2 received a transplant, and none occluded.
No patients were lost to follow-up.
The patients with restenosis had further interventions
to reopen the stenoses. Life-table analysis at 3 and 6
months showed that primary patency was 39% in the bare
stent group and 82% in the stent graft group. One-year
primary patency was 0% in the bare stent group and 32% in
the stent graft group (log-rank test: 2 9.28, P .0023;
hazard ratio, 4.086; 95% CI, 1.9-20.3; Fig 1; Appendix I,
online only). One-year functional patency was 90% in the
bare stent group and 100% in the stent graft group (log-
rank test: P  .293; Fig 2; Appendix II, online only).
There were 1.9 interventions per patient-year in the
Fig 1. Life-table analysis of the primary patency rates for 25
consecutive angioplasties of the cephalic arch using bare stents
(triangles) or stent grafts (circles). The broken line indicates a
standard error 10%.
Fig 2. Life-table analysis of the functional patency rates for 25
consecutive angioplasties of the cephalic arch using bare stents
(circles) or stent grafts (triangles). The broken line indicates a
standard error 10%.bare stent group and 0.9 in the stent-graft group (P .02).
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ventional procedures for restenosis during the follow up
period. All had in-segment lesions in the bare portion of the
stent. All 10 of the 12 patients in the bare stent group who
had interventional procedures had in-stent restenosis or
occlusion in the same site as the original stenosis that led to
stenting.
DISCUSSSION
The cephalic arch is the most frequent location for
stenosis of upper arm dysfunctional autogenous AVAs,
comprising 30% to 55% of all upper arm access stenosis
sites.16 This lesion is known to have a very poor outcome
after angioplasty, with a 6-month primary patency rate of
42%,7 which is below the 50% unassisted patency rate
recommended for intervention after access stenosis.17
In the past we used bare stents for early recurrent
stenosis in the cephalic arch, but we noted rapid develop-
ment of in-stent restenosis due to ingrowth of neointimal
hyperplasia.18 Our use of stent grafts in extravasations or
ruptured stenoses after PTA and in false aneurysms, where
we were obliged to use stent grafts to prevent a leak, led to
the observation that development of in-stent stenosis was
rare in stent grafts.
This study compared the use of bare stents with stent
grafts in early restenosis of the cephalic arch after previous
balloon dilatation. The two groups were comparable in age,
degree of stenosis, length of stenosis, and number of pre-
vious PTAs (Table I). Our results showed a clear advantage
for stent grafts over bare stents. Statistical significance was
reached after only half of the planned 50 patients were
recruited (Table III), causing us to cease accrual for ethical
reasons. This significant difference continued to be seen
after follow-up of 1 year (Fig 1), even though follow-up
had been terminated in half of the patients in each group
because of death or renal transplantation. A significantly
higher rate of interventions in the bare stent group was also
noted during long-term follow-up.
Nine of the 25 patients died at mean follow up of 13.7
months. This is a reflection of the fragile patient population
that we are dealing with and seems to support the utiliza-
tion of endovascular interventions rather than aggressive
surgical interventions to maintain access patency, adequate
dialysis dose delivery, and quality of life.
Patent vascular access is essential for the treatment and
survival of patients with end-stage renal disease. Autoge-
nous AVA is preferred as the access for hemodialysis, being
more durable and having a lower complication rate than
prosthetic AVA. The creation of a prosthetic AVA for
hemodialysis should be done only in patients in whom it is
not possible to create an autogenous AVA.19 Preoperative
assessment with color-coded Doppler ultrasonography,
combined with venography when necessary, is an essential
adjunct to clinical examination in making this decision.10
Vascular access monitoring to detect and correct steno-
ses that develop over differing periods of time canminimize
or avoid access occlusion. This enables vascular accesses to
be salvaged by elective intervention rather than be replacedor corrected by emergency interventions.20 Access dysfunc-
tion contributes to inadequate dialysis dose delivery that is
independently related to patient noncompliance, low dial-
ysis prescription, catheter use, and access thrombosis. Each
0.1 decrease in Kt/V is significantly related to increased
hospitalization and inpatient expenditure.21 In our center,
patients with prosthetic AVAs or with stents, or both, are
routinely examined by Doppler ultrasound imaging every 3
months. Patients with autogenous AVAs without stents are
examined every 6 to 12 months.10,11
In our own practice, every dialysis access is of the
utmost value because of the low availability of organs for
transplantation in our locale. This circumstance has driven
us to try to improve patency rates by all means available.
Responsibility for the patient does not end with successful
access construction. Maintenance of patency requires con-
stant surveillance and prophylactic interventions that can be
used in an overall integrated approach such as a vascular
access management program. In addition to the planning
of access construction, our access center environment in-
cludes a follow-up clinic inside the access unit enabling
liberal use of Doppler ultrasound imaging as deemed nec-
essary by the surgeon, even if the patient has only come to
have sutures removed. Patients are then referred for diag-
nostic and preemptivemaintenance angioplasty if stenosis is
suspected at any stage in their follow-up program. Doppler
ultrasound imaging was used in this study to detect stenosis
during normal follow-up, not as a criterion for entry into
the study. Patients with early restenosis after previous PTA
whose stenosis was detected in this fashion were then
offered entry into the study.
AVA stenosis is usually treated initially with PTA,
sometimes with cutting balloons or high-pressure balloons
for stubborn stenoses. A residual stenosis of 30% is rec-
ommended to avoid restenosis after balloon dilatation.12,22
Stent deployment is also not without problems, being
susceptible to in-stent restenosis due to intimal hyperpla-
sia.23 Stents are therefore usually reserved for particularly
difficult situations, including residual stenosis of 30%
after balloon dilatation, recurrent stenoses that occur 6
months of balloon dilatation, or for failure of balloon
dilatation.4,7,24 Even so, the use of stent grafts for AVAs is
still not common.
The improved primary patency of stent grafts compared
with bare stents that was demonstrated in this study caused
us to abandon the use of bare stents in native vein AVAs.
However, stenting of the cephalic arch was associated with
important technical issues that were experienced with the
application of this technique. The Fluency stent graft
should be long enough (6 cm) to cover the whole length
of the cephalic arch, otherwise the cephalic vein might kink
at the peripheral landing zone of the stent graft, causing an
iatrogenic restenosis that requires the placement of an
additional stent graft to reform the arch (Fig 3). This
preventable stenosis can cause occlusion of the AVA if it is
not corrected. The problem of kinking may be related to
the inflexibility of the stents used in the study. Although the
Gore Hemobahn/Viabahn Endoprosthesis (W. L. Gore
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flexible enough for the cephalic arch, the manufacturer
does not produce a comparable bare stent so it would not
have been appropriate for use in our study.
It is also important that the stent graft be placed exactly
at the confluence of the cephalic vein with the axillary/
subclavian vein. If it protrudes into the confluence, it may
cause turbulence and occlusion of the axillary/subclavian
vein. No axillary vein occlusion developed in any study
Fig 3. A, Kinking of the cephalic vein by the end of a stent-graft
due to the inherent inflexibility of the stent. B, The kink is
straightened by deployment of an overlapping stent-graft more
peripherally, in keeping with the natural curve of the cephalic arch,
and ending in the straight peripheral segment of the cephalic vein.patients, but it has occurred after deployment of stent graftsin other patients. Some radiologists extrapolate from arte-
rial stenting and do not see bulging of the stent into the
subclavian vein as a problem. Despite its rarity, however, we
have seen a few cases of axillary/subclavian vein occlusion
diagnosed in preoperative venography for new access, even
with minimal protrusion. This is important because that
arm is no longer available for AVA construction.
During the study we assumed that in-segment stenoses
in stent grafts developed due to suboptimal positioning
leaving a short segment of the recurrent stenotic lesion at
the end of the stent. However, the long-term results show
that most of these stenoses appeared at both bare ends of
the stent graft (Fig 4), suggesting that this portion of the
stent should also be covered, leaving no part bare whatso-
ever. The stenosis may be due to intimal hyperplasia occur-
ring in the metallic mesh interstices of bare stents that does
not occur in stents covered by PTFE. This appears to
indicate that stenting of stenosis caused by intimal hyper-
plasia should only be done with stents completely covered
by PTFE to prevent recurrence of the intimal hyperplasia.
All of the patients in the study had autogenous
brachial–cephalic AVAs. Cephalic arch stenosis was not a
cause of access dysfunction in other types of AVA such as
radial–cephalic and prosthetic AVAs. This may be ex-
plained by the possibility that the blood flow in radial–
cephalic AVAs is preferentially directed to the basilic vein
rather than the cephalic vein and by the fact that all pros-
thetic AVAs in our center are planned to be anastomosed to
the basilic or brachial vein.
A relative limitation of this study is the small number of
patients resulting in wide confidence intervals. However,
with the appearance of such a large and significant differ-
ence after such a short accrual period, the addition of more
patients was impossible to justify on ethical grounds, and it
is difficult to conceive of such a study being performed in
the future for the same reason. This large difference was
completely unexpected, and the investigators requested an
interim statistical analysis.
At the end of the follow-up period, nine patients had
died and two had undergone renal transplantation. Despite
the small numbers remaining, the significant difference in
restenosis rates continued to be observed. Life-table analy-
sis showed a significantly improved patency rate for stent
grafts vs bare stents (Fig 1). This difference was also re-
flected by the significant difference in reintervention rates
between the two groups in favor of the stent-graft group.
We have begun collecting data for all covered stents in
our center for comparison with the results of bare stents
used in the past because further randomization of patients
appeared unjustifiable in view of our results.
CONCLUSION
Restenosis rates in recurrent cephalic arch restenosis were
significantly better for angioplasty using stent grafts compared
with bare stents. This study altered our usage of stents for
venous stenoses in AVA for hemodialysis by eliminating bare
nitinol stents in favor of stent grafts. We suggest that in
patients where intimal hyperplasia is a possibility, stenting
JOURNAL OF VASCULAR SURGERY
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PTFE, while paying careful attention to technical factors such
as stent flexibility, stent length, and accurate deployment in
relation to the position of the stenotic lesion.
We thank Dr Irina Balla for technical assistance in
processing the data for this study and Dr Anthony G.
Verstandig for help in preparing the manuscript.
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A B C D E F G
Interval, mon No. at risk No. failed No. withdrawn Interval failure rate Cumulative patency rate, % Standard error, %
Bare stents
0-1 12 0 0 0.0000 100.00 0
1-2 12 0 0 0.0000 100.00 0
2-3 12 7 1 0.6087 39.13 8.813008
3-4 4 0 1 0.0000 39.13 15.26458
4-5 3 0 0 0.0000 39.13 17.62602
5-6 3 0 0 0.0000 39.13 17.62602
6-7 3 1 0 0.3333 26.09 12.94862









0-1 13 0 0 0.0000 100.00 0
1-2 13 0 2 0.0000 100.00 0
2-3 11 2 0 0.1818 81.82 10.51894
3-4 9 0 0 0.0000 81.82 11.62913
4-5 9 0 0 0.0000 81.82 11.62913
5-6 9 0 1 0.0000 81.82 11.62913
6-7 8 0 1 0.0000 81.82 12.33456
7-8 7 0 1 0.0000 81.82 13.18619
8-9 6 0 1 0.0000 81.82 14.24272
9-10 5 1 1 0.2222 63.64 17.16145
10-11 3 0 1 0.0000 63.64 22.15534
11-12 2 1 0 0.5000 31.82 18.57782
12-13 1 0 0 0.0000 31.82 26.273
13-14 1 0 0 0.0000 31.82 26.273
14-15 1 0 0 0.0000 31.82 26.273
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6 Shemesh et al 1531.e2Appendix II (online only). Functional patency rates for bare stents and stent grafts by life-table analysis
A B C D E F G
Interval, mon No. at risk No. failed No. withdrawn Interval failure rate Cumulative patency rate, % Standard error, %
Bare stents
0-1 12 0 0 0.0000 100.00 0
1-2 12 0 0 0.0000 100.00 0
2-3 12 0 1 0.0000 100.00 0
3-4 11 0 1 0.0000 100.00 0
4-5 10 0 0 0.0000 100.00 0
5-6 10 1 0 0.1000 90.00 9
6-7 9 0 0 0.0000 90.00 9.486833
7-8 9 0 0 0.0000 90.00 9.486833
8-9 9 0 0 0.0000 90.00 9.486833
9-10 9 0 0 0.0000 90.00 9.486833
10-11 9 0 0 0.0000 90.00 9.486833
11-12 9 0 0 0.0000 90.00 9.486833
12-13 9 0 1 0.0000 90.00 9.486833
13-14 8 0 1 0.0000 90.00 10.06231
14-15 7 0 0 0.0000 90.00 10.75706
Stent grafts
0-1 13 0 0 0.0000 100.00 0
1-2 13 0 2 0.0000 100.00 0
2-3 11 0 0 0.0000 100.00 0
3-4 11 0 0 0.0000 100.00 0
4-5 11 0 0 0.0000 100.00 0
5-6 11 0 1 0.0000 100.00 0
6-7 10 0 1 0.0000 100.00 0
7-8 9 0 1 0.0000 100.00 0
8-9 8 0 1 0.0000 100.00 0
9-10 7 0 1 0.0000 100.00 0
10-11 6 0 1 0.0000 100.00 0
11-12 5 0 0 0.0000 100.00 0
12-13 5 0 0 0.0000 100.00 0
13-14 5 0 0 0.0000 100.00 0
14-15 5 0 0 0.0000 100.00 0
